{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T16:11:40Z","timestamp":1775146300553,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["Project 197660 and 213795"],"award-info":[{"award-number":["Project 197660 and 213795"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["Project 197660 and 213795"],"award-info":[{"award-number":["Project 197660 and 213795"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["Project 197660 and 213795"],"award-info":[{"award-number":["Project 197660 and 213795"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Non-alcoholic steatohepatitis (NASH) is a chronic disease characterized by inflammation, steatosis, and liver fibrosis. The liver is particularly affected by alterations in lipid metabolism. Our aim was to evaluate the effect of \u03b2-hydroxyphosphocarnitine (\u03b2-HPC) on NASH induced in rats.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>NASH was produced via the ad libitum daily chronic administration of a fructose solution (400\u00a0kcal) for 9\u00a0weeks, an oral dose of fat solution (16\u00a0kcal) for 7\u00a0weeks and a subcutaneous injection of CCl<jats:sub>4<\/jats:sub> (30%) two times a week for 2\u00a0weeks to Wistar rats. To evaluate the effect of \u03b2-HPC, a dose of 100\u00a0mg\/kg was administered perorally for 4\u00a0weeks and its biochemical and hepatic effects on rats with NASH were analyzed. Serum levels of glucose, triglycerides, cholesterol, and liver enzymes were quantified. Histological changes were evaluated on slices stained with H&amp;E, trichromic and PAS. Glycogen content was measured in liver samples. \u03b1-SMA and SREBP-1 immunopositive cells were identified in liver tissue.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>NASH was characterized by elevated triglycerides, elevated liver damage enzymes, and the presence of necrosis, inflammation, steatosis, and fibrosis. Significant amounts of glycogen were found, along with \u03b1-SMA positive cells in fibrosis areas. The over-expression of SREBP-1 in cytoplasm and nuclei was evident. Animals with NASH treated with \u03b2-HPC showed a significant reduction in inflammation, necrosis, and glycogen content in the liver. A reduction in \u03b1-SMA and SREBP-1 immunopositive cells correlated with a significant reduction in the degree of fibrosis and steatosis found in liver tissue. \u03b2-HPC reduced the levels of ALP and GGT, and significantly reduced triglyceride levels. Animals treated with \u03b2-HPC did not show any alterations in liver enzyme function.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our research shows that \u03b2-HPC can improve liver function and morphology in the case of NASH induced in rats, suggesting \u03b2-HPC could be potentially used in the treatment of NASH.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40360-022-00613-2","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T09:04:10Z","timestamp":1664442250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["\u03b2-Hydroxyphosphocarnitine modifies fibrosis, steatosis and improves liver function in non-alcoholic steatohepatitis induced in rats"],"prefix":"10.1186","volume":"23","author":[{"given":"Janet","family":"S\u00e1nchez-Quevedo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Ocampo-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Alvarez-Ayala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anah\u00ed","family":"Rodr\u00edguez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel Angel","family":"Duarte-V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge Luis","family":"Rosado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lourdes","family":"Rodr\u00edguez-Fragoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"issue":"6","key":"613_CR1","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jhepr.2019.10.008","volume":"1","author":"K Hallsworth","year":"2019","unstructured":"Hallsworth K, Adams LA. Lifestyle modification in NAFLD\/NASH: Facts and figures. JHEP Rep. 2019;1(6):468\u201379. https:\/\/doi.org\/10.1016\/j.jhepr.2019.10.008.","journal-title":"JHEP Rep"},{"key":"613_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13098-020-00570-y","volume":"12","author":"AF Godoy-Matos","year":"2020","unstructured":"Godoy-Matos AF, Silva J\u00fanior WS, Valerio CM. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr. 2020;12:60. https:\/\/doi.org\/10.1186\/s13098-020-00570-y.","journal-title":"Diabetol Metab Syndr"},{"key":"613_CR3","doi-asserted-by":"publisher","first-page":"101143","DOI":"10.1016\/j.molmet.2020.101143","volume":"50","author":"KK Bence","year":"2021","unstructured":"Bence KK, Birnbaum MJ. Metabolic drivers of non-alcoholic fatty liver disease. Mol Metab. 2021;50:101143. https:\/\/doi.org\/10.1016\/j.molmet.2020.101143.","journal-title":"Mol Metab"},{"issue":"4","key":"613_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jhepr.2019.08.002","volume":"1","author":"S Albhaisi","year":"2019","unstructured":"Albhaisi S, Chowdhury A, Sanyal AJ. Non-alcoholic fatty liver disease in lean individuals. JHEP Rep. 2019;1(4):329\u201341. https:\/\/doi.org\/10.1016\/j.jhepr.2019.08.002.","journal-title":"JHEP Rep"},{"key":"613_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2020.113040","volume":"225","author":"A Bovolini","year":"2020","unstructured":"Bovolini A, Garcia J, Andrade MA, Duarte JA. Relative contribution of fat diet and physical inactivity to the development of metabolic syndrome and non-alcoholic fat liver disease in Wistar rats. Physiol Behav. 2020;225: 113040. https:\/\/doi.org\/10.1016\/j.physbeh.2020.113040.","journal-title":"Physiol Behav"},{"issue":"9","key":"613_CR6","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3390\/nu9090981","volume":"9","author":"KW Ter Horst","year":"2017","unstructured":"Ter Horst KW, Serlie MJ. Fructose consumption, lipogenesis, and non-alcoholic fatty liver disease. Nutrients. 2017;9(9):981. https:\/\/doi.org\/10.3390\/nu9090981.","journal-title":"Nutrients"},{"issue":"2","key":"613_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.bpg.2017.04.005","volume":"31","author":"ME Zoubek","year":"2017","unstructured":"Zoubek ME, Trautwein C, Strnad P. Reversal of liver fibrosis: from fiction to reality. Best Pract Res Clin Gastroenterol. 2017;31(2):129\u201341. https:\/\/doi.org\/10.1016\/j.bpg.2017.04.005.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"11","key":"613_CR8","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1016\/j.ajpath.2020.08.002","volume":"190","author":"D Zheng","year":"2020","unstructured":"Zheng D, Jiang Y, Qu C, et al. Pyruvate Kinase M2 Tetramerization Protects against Hepatic Stellate Cell Activation and Liver Fibrosis. Am J Pathol. 2020;190(11):2267\u201381. https:\/\/doi.org\/10.1016\/j.ajpath.2020.08.002.","journal-title":"Am J Pathol"},{"issue":"1","key":"613_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/1751-2980.12830","volume":"21","author":"JT Tang","year":"2020","unstructured":"Tang JT, Mao YM. Development of new drugs for the treatment of nonalcoholic steatohepatitis. J Dig Dis. 2020;21(1):3\u201311. https:\/\/doi.org\/10.1111\/1751-2980.12830.","journal-title":"J Dig Dis"},{"issue":"2","key":"613_CR10","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jhep.2017.10.015","volume":"68","author":"MA Konerman","year":"2018","unstructured":"Konerman MA, Jones JC, Harrison SA. Pharmacotherapy for NASH: Current and emerging. J Hepatol. 2018;68(2):362\u201375. https:\/\/doi.org\/10.1016\/j.jhep.2017.10.015.","journal-title":"J Hepatol"},{"issue":"2","key":"613_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.rgmx.2017.10.003","volume":"83","author":"C Moctezuma-Vel\u00e1zquez","year":"2018","unstructured":"Moctezuma-Vel\u00e1zquez C. Current treatment for non-alcoholic fatty liver disease. Tratamiento actual de la enfermedad por h\u00edgado graso no alcoh\u00f3lico. Rev Gastroenterol Mex (Engl Ed). 2018;83(2):125\u201333. https:\/\/doi.org\/10.1016\/j.rgmx.2017.10.003.","journal-title":"Rev Gastroenterol Mex (Engl Ed)"},{"issue":"6","key":"613_CR12","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.jceh.2019.06.003","volume":"9","author":"S Kothari","year":"2019","unstructured":"Kothari S, Dhami-Shah H, Shah SR. Antidiabetic drugs and statins in nonalcoholic fatty liver disease. J Clin Exp Hepatol. 2019;9(6):723\u201330. https:\/\/doi.org\/10.1016\/j.jceh.2019.06.003.","journal-title":"J Clin Exp Hepatol"},{"issue":"3","key":"613_CR13","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.clinthera.2021.01.021","volume":"43","author":"P Campbell","year":"2021","unstructured":"Campbell P, Symonds A, Barritt AS 4th. Therapy for nonalcoholic fatty liver disease: current options and future directions. Clin Ther. 2021;43(3):500\u201317. https:\/\/doi.org\/10.1016\/j.clinthera.2021.01.021.","journal-title":"Clin Ther"},{"issue":"4","key":"613_CR14","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/bcpt.12019","volume":"112","author":"J Reyes-Esparza","year":"2013","unstructured":"Reyes-Esparza J, Mendoza-Rivera B, De la Cruz-Cordero R, et al. Pharmacological evaluation of a \u03b2-hydroxyphosphonate analogue of l-carnitine in obese Zucker fa\/fa rats. Basic Clin Pharmacol Toxicol. 2013;112(4):222\u20138. https:\/\/doi.org\/10.1111\/bcpt.12019.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1\u20132","key":"613_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000328772","volume":"88","author":"A G\u00f3mez-Sol\u00eds","year":"2011","unstructured":"G\u00f3mez-Sol\u00eds A, De la Cruz-Cordero R, Avalos-Soriano A, Duarte-V\u00e1zquez MA, Reyes-Esparza J, Rodr\u00edguez-Fragoso L. Efficacy and safety of two analogs of L-carnitine on rats made insulin resistant by a high-fructose diet. Pharmacology. 2011;88(1\u20132):10\u20137. https:\/\/doi.org\/10.1159\/000328772.","journal-title":"Pharmacology"},{"key":"613_CR16","doi-asserted-by":"publisher","unstructured":"Reyes-Esparza J, Mendoza-Rivera B, De la Cruz-Cordero R, Duarte-V\u00e1zquez M. A, Rosado JL, Rodr\u00edguez-Fragoso L. Preclinical safety assessment of \u03b2-hydroxyphospho-carnitine. Toxicol Int. 2016; 23(2): 170. https:\/\/doi.org\/10.22506\/ti\/2016\/v23\/i2\/146697","DOI":"10.22506\/ti\/2016\/v23\/i2\/146697"},{"issue":"1\u20132","key":"613_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1159\/000366205","volume":"94","author":"J Reyes-Esparza","year":"2014","unstructured":"Reyes-Esparza J, Mendoza-Rivera B, De la Cruz-Cordero R, Duarte-V\u00e1zquez M\u00c1, Rosado JL, Rodr\u00edguez-Fragoso L. Pharmacokinetic and pharmacological effects of \u03b2-hydroxyphosphocarnitine in animal models. Pharmacology. 2014;94(1\u20132):90\u20138. https:\/\/doi.org\/10.1159\/000366205.","journal-title":"Pharmacology"},{"key":"613_CR18","volume-title":"Guide for the Care and Use of Laboratory Animals","author":"National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals","year":"2011","unstructured":"National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals. 8th ed. Washington (DC): National Academies Press (US); 2011.","edition":"8"},{"issue":"3","key":"613_CR19","doi-asserted-by":"publisher","first-page":"511","DOI":"10.5604\/01.3001.0011.7396","volume":"17","author":"YP Zheng","year":"2018","unstructured":"Zheng YP, Zhong XY, Huang YS, Zheng CB. HCBP6 Is Involved in the Development of Hepatic Steatosis Induced by High-Fat Diet and CCL4 in Rats. Ann Hepatol. 2018;17(3):511\u20138. https:\/\/doi.org\/10.5604\/01.3001.0011.7396.","journal-title":"Ann Hepatol"},{"issue":"16","key":"613_CR20","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1111\/bph.15178","volume":"177","author":"E Lilley","year":"2020","unstructured":"Lilley E, Stanford SC, Kendall DE, Alexander SPH, Cirino G, Docherty JR, et al. ARRIVE 2.0 and the British Journal of pharmacology: updated guidance for 2020. Br J Pharmacol. 2020;177(16):3611\u20136.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"613_CR21","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jhep.2007.07.006","volume":"47","author":"ZD Goodman","year":"2007","unstructured":"Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol. 2007;47(4):598\u2013607. https:\/\/doi.org\/10.1016\/j.jhep.2007.07.006.","journal-title":"J Hepatol"},{"key":"613_CR22","doi-asserted-by":"publisher","unstructured":"Shojaei Zarghani S, Soraya H, Zarei L. and Alizadeh M. Comparison of Three Different Diet-Induced Non Alcoholic Fatty Liver Disease Protocols in Rats: A Pilot Study. Pharm Sci. 2016;9\u201315. https:\/\/doi.org\/10.15171\/PS.2016.03","DOI":"10.15171\/PS.2016.03"},{"issue":"5","key":"613_CR23","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1177\/1559827618766483","volume":"12","author":"J Fuhrman","year":"2018","unstructured":"Fuhrman J. The hidden dangers of fast and processed food. Am J Lifestyle Med. 2018;12(5):375\u201381. https:\/\/doi.org\/10.1177\/1559827618766483.","journal-title":"Am J Lifestyle Med"},{"key":"613_CR24","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.nutres.2018.11.003","volume":"62","author":"N Fakhoury-Sayegh","year":"2019","unstructured":"Fakhoury-Sayegh N, Trak-Smayra V, Sayegh R, et al. Fructose threshold for inducing organ damage in a rat model of nonalcoholic fatty liver disease. Nutr Res. 2019;62:101\u201312. https:\/\/doi.org\/10.1016\/j.nutres.2018.11.003.","journal-title":"Nutr Res"},{"issue":"3","key":"613_CR25","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3390\/nu9030230","volume":"9","author":"P Jegatheesan","year":"2017","unstructured":"Jegatheesan P, De Bandt JP. Fructose and NAFLD: the multifaceted aspects of fructose metabolism. Nutrients. 2017;9(3):230. https:\/\/doi.org\/10.3390\/nu9030230.","journal-title":"Nutrients"},{"issue":"5","key":"613_CR26","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.jhep.2018.01.019","volume":"68","author":"T Jensen","year":"2018","unstructured":"Jensen T, Abdelmalek MF, Sullivan S, et al. Fructose and sugar: a major mediator of non-alcoholic fatty liver disease. J Hepatol. 2018;68(5):1063\u201375. https:\/\/doi.org\/10.1016\/j.jhep.2018.01.019.","journal-title":"J Hepatol"},{"issue":"4","key":"613_CR27","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.3390\/nu13041314","volume":"13","author":"A Federico","year":"2021","unstructured":"Federico A, Rosato V, Masarone M, et al. The role of fructose in non-alcoholic steatohepatitis: old relationship and new insights. Nutrients. 2021;13(4):1314. https:\/\/doi.org\/10.3390\/nu13041314.","journal-title":"Nutrients"},{"issue":"4","key":"613_CR28","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3390\/biom10040496","volume":"10","author":"B Dewdney","year":"2020","unstructured":"Dewdney B, Roberts A, Qiao L, George J, Hebbard L. A sweet connection? Fructose\u2019s role in hepatocellular carcinoma. Biomolecules. 2020;10(4):496. https:\/\/doi.org\/10.3390\/biom10040496.","journal-title":"Biomolecules"},{"issue":"5","key":"613_CR29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3238\/arztebl.m2021.0010","volume":"118","author":"S Stricker","year":"2021","unstructured":"Stricker S, Rudloff S, Geier A, Steveling A, Roeb E, Zimmer KP. Fructose consumption-free sugars and their health effects. Dtsch Arztebl Int. 2021;118(5):71\u20138. https:\/\/doi.org\/10.3238\/arztebl.m2021.0010.","journal-title":"Dtsch Arztebl Int"},{"key":"613_CR30","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.2147\/DDDT.S315724","volume":"15","author":"JM Fraile","year":"2021","unstructured":"Fraile JM, Palliyil S, Barelle C, Porter AJ, Kovaleva M. Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease. Drug Des Devel Ther. 2021;15:3997\u20134009. https:\/\/doi.org\/10.2147\/DDDT.S315724.","journal-title":"Drug Des Devel Ther"},{"issue":"26","key":"613_CR31","doi-asserted-by":"publisher","first-page":"e6761","DOI":"10.1097\/MD.0000000000006761","volume":"96","author":"PJ Patel","year":"2017","unstructured":"Patel PJ, Hayward KL, Rudra R, et al. Multimorbidity and polypharmacy in diabetic patients with NAFLD: Implications for disease severity and management. Medicine (Baltimore). 2017;96(26):e6761. https:\/\/doi.org\/10.1097\/MD.0000000000006761.","journal-title":"Medicine (Baltimore)"},{"key":"613_CR32","doi-asserted-by":"publisher","first-page":"104554","DOI":"10.1016\/j.phrs.2019.104554","volume":"151","author":"M Askarpour","year":"2020","unstructured":"Askarpour M, Hadi A, Miraghajani M, Symonds ME, Sheikhi A, Ghaedi E. Beneficial effects of l-carnitine supplementation for weight management in overweight and obese adults: An updated systematic review and dose-response meta-analysis of randomized controlled trials. Pharmacol Res. 2020;151:104554. https:\/\/doi.org\/10.1016\/j.phrs.2019.104554.","journal-title":"Pharmacol Res"},{"key":"613_CR33","doi-asserted-by":"publisher","first-page":"626319","DOI":"10.1155\/2014\/626319","volume":"2014","author":"AA El-Sheikh","year":"2014","unstructured":"El-Sheikh AA, Rifaai RA. Peroxisome Proliferator Activator Receptor (PPAR)- \u03b3 Ligand, but Not PPAR- \u03b1, Ameliorates Cyclophosphamide-Induced Oxidative Stress and Inflammation in Rat Liver. PPAR Res. 2014;2014:626319. https:\/\/doi.org\/10.1155\/2014\/626319.","journal-title":"PPAR Res"},{"issue":"1","key":"613_CR34","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s12876-020-01467-w","volume":"20","author":"G Zhang","year":"2020","unstructured":"Zhang G, Wang X, Chung TY, et al. Carbon tetrachloride (CCl4) accelerated development of non-alcoholic fatty liver disease (NAFLD)\/steatohepatitis (NASH) in MS-NASH mice fed western diet supplemented with fructose (WDF). BMC Gastroenterol. 2020;20(1):339. https:\/\/doi.org\/10.1186\/s12876-020-01467-w.","journal-title":"BMC Gastroenterol"},{"key":"613_CR35","doi-asserted-by":"publisher","first-page":"152782","DOI":"10.1016\/j.phymed.2018.12.005","volume":"59","author":"Y Yang","year":"2019","unstructured":"Yang Y, Li J, Wei C, et al. Amelioration of nonalcoholic fatty liver disease by swertiamarin in fructose-fed mice. Phytomedicine. 2019;59:152782. https:\/\/doi.org\/10.1016\/j.phymed.2018.12.005.","journal-title":"Phytomedicine"},{"issue":"7","key":"613_CR36","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","volume":"158","author":"RF Schwabe","year":"2020","unstructured":"Schwabe RF, Tabas I, Pajvani UB. Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis. Gastroenterology. 2020;158(7):1913\u201328. https:\/\/doi.org\/10.1053\/j.gastro.2019.11.311.","journal-title":"Gastroenterology"},{"issue":"1","key":"613_CR37","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1038\/s41598-019-39112-6","volume":"9","author":"AB Marcher","year":"2019","unstructured":"Marcher AB, Bendixen SM, Terkelsen MK, et al. Transcriptional regulation of Hepatic Stellate Cell activation in NASH. Sci Rep. 2019;9(1):2324. https:\/\/doi.org\/10.1038\/s41598-019-39112-6.","journal-title":"Sci Rep"},{"issue":"11","key":"613_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0340-1","volume":"51","author":"YR Kim","year":"2019","unstructured":"Kim YR, Lee EJ, Shin KO, et al. Hepatic triglyceride accumulation via endoplasmic reticulum stress-induced SREBP-1 activation is regulated by ceramide synthases. Exp Mol Med. 2019;51(11):1\u201316. https:\/\/doi.org\/10.1038\/s12276-019-0340-1.","journal-title":"Exp Mol Med"},{"issue":"3","key":"613_CR39","doi-asserted-by":"publisher","first-page":"332","DOI":"10.14218\/JCTH.2017.00061","volume":"6","author":"A Moslehi","year":"2018","unstructured":"Moslehi A, Hamidi-Zad Z. Role of SREBPs in liver diseases: a mini-review. J Clin Transl Hepatol. 2018;6(3):332\u20138. https:\/\/doi.org\/10.14218\/JCTH.2017.00061.","journal-title":"J Clin Transl Hepatol"},{"issue":"3","key":"613_CR40","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.toxlet.2012.06.002","volume":"212","author":"C Zhang","year":"2012","unstructured":"Zhang C, Chen X, Zhu RM, et al. Endoplasmic reticulum stress is involved in hepatic SREBP-1c activation and lipid accumulation in fructose-fed mice. Toxicol Lett. 2012;212(3):229\u201340. https:\/\/doi.org\/10.1016\/j.toxlet.2012.06.002.","journal-title":"Toxicol Lett"},{"issue":"2","key":"613_CR41","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1172\/JCI96702","volume":"128","author":"SA Hannou","year":"2018","unstructured":"Hannou SA, Haslam DE, McKeown NM, Herman MA. Fructose metabolism and metabolic disease. J Clin Invest. 2018;128(2):545\u201355. https:\/\/doi.org\/10.1172\/JCI96702.","journal-title":"J Clin Invest"},{"issue":"1","key":"613_CR42","first-page":"1","volume":"7","author":"A Yousefinejad","year":"2018","unstructured":"Yousefinejad A, Siassi F, Javanbakht MH, et al. Effect of Genistein and L-carnitine and their combination on lipid profile and inflammatory cytokines in experimental nephrotic syndrome. Rep Biochem Mol Biol. 2018;7(1):1\u20138.","journal-title":"Rep Biochem Mol Biol"},{"key":"613_CR43","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/1743-7075-7-66","volume":"7","author":"R Siegner","year":"2010","unstructured":"Siegner R, Heuser S, Holtzmann U, et al. Lotus leaf extract and L-carnitine influence different processes during the adipocyte life cycle. Nutr Metab (Lond). 2010;7:66. https:\/\/doi.org\/10.1186\/1743-7075-7-66.","journal-title":"Nutr Metab (Lond)"},{"issue":"1","key":"613_CR44","doi-asserted-by":"publisher","first-page":"FSO250","DOI":"10.4155\/fsoa-2017-0083","volume":"4","author":"KS Nallagangula","year":"2017","unstructured":"Nallagangula KS, Nagaraj SK, Venkataswamy L, Chandrappa M. Liver fibrosis: a compilation on the biomarkers status and their significance during disease progression. Future Sci OA. 2017;4(1):FSO250. https:\/\/doi.org\/10.4155\/fsoa-2017-0083.","journal-title":"Future Sci OA"},{"issue":"6","key":"613_CR45","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/MCG.0000000000000116","volume":"48","author":"DR LaBrecque","year":"2014","unstructured":"Review Team, LaBrecque DR, Abbas Z, et al. World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol. 2014;48(6):467\u201373. https:\/\/doi.org\/10.1097\/MCG.0000000000000116.","journal-title":"J Clin Gastroenterol"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-022-00613-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-022-00613-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-022-00613-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T09:05:17Z","timestamp":1664442317000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-022-00613-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["613"],"URL":"https:\/\/doi.org\/10.1186\/s40360-022-00613-2","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]},"assertion":[{"value":"17 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Research Ethics Review Committee from the Autonomous University of the State of Morelos (Approval No. 2756). All experimental procedures followed the Institutional Guides for practice in animals and Welfare Act Public Laws of Morelos State (Mexico) and the Guide for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}